Estradiol repression of tumor necrosis factor-α transcription requires estrogen receptor activation function-2 and is enhanced by coactivators

被引:166
作者
An, JP
Ribeiro, RCJ
Webb, P
Gustafsson, JÅ
Kushner, PJ
Baxter, JD
Leitman, DC
机构
[1] Univ Calif San Francisco, Ctr Reprod Sci, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Metab Res Unit, San Francisco, CA 94143 USA
[3] Univ Brasilia, Dept Pharmaceut Sci, BR-70910900 Brasilia, DF, Brazil
[4] Karolinska Inst, Novum, Dept Med Nutr, S-14186 Huddinge, Sweden
关键词
D O I
10.1073/pnas.96.26.15161
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The tumor necrosis factor-alpha (TNF-alpha) promoter was used to explore the molecular mechanisms of estradiol (E-2)-dependent repression of gene transcription. E-2 inhibited basal activity and abolished TNF-alpha activation of the TNF-alpha promoter. The E-2-inhibitory element was mapped to the -125 to -82 region of the TNF-alpha promoter, known as the TNF-responsive element (TNF-RE), An AP-1-like site in the TNF-RE is essential for repression activity. Estrogen receptor (ER) beta is more potent than ER alpha at repressing the -1044 TNF-alpha promoter and the TNF-RE upstream of the herpes simplex virus thymidine kinase promoter, but weaker at activating transcription through an estrogen response element. The activation function-2 (AF-2) surface in the ligand-binding domain is required for repression, because anti-estrogens and AF-2 mutations impair repression. The requirement of the AF-2 surface for repression is probably due to its capacity to recruit p160 coactivators or related coregulators, because overexpressing the coactivator glucocorticoid receptor interacting protein-1 enhances repression, whereas a glucocorticoid receptor interacting protein-1 mutant unable to interact with the AF-2 surface is ineffective. Furthermore, receptor interacting protein 140 prevents repression by ERP, probably by interacting with the AF-2 surface and blocking the binding of endogenous coactivators, These studies demonstrate that E-2-mediated repression requires the AF-2 surface and the participation of coactivators or other coregulatory proteins.
引用
收藏
页码:15161 / 15166
页数:6
相关论文
共 50 条
[1]   Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency [J].
Ammann, P ;
Rizzoli, R ;
Bonjour, JP ;
Bourrin, S ;
Meyer, JM ;
Vassalli, P ;
Garcia, I .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (07) :1699-1703
[2]   Reproductive endocrine and endometrial effects of raloxifene hydrochloride, a selective estrogen receptor modulator, in women with regular menstrual cycles [J].
Baker, VL ;
Draper, M ;
Paul, S ;
Allerheiligen, S ;
Glant, M ;
Shifren, J ;
Jaffe, RB .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (01) :6-13
[3]   Hormone replacement therapy, heart disease, and other considerations [J].
Barrett-Connor, E ;
Grady, D .
ANNUAL REVIEW OF PUBLIC HEALTH, 1998, 19 :55-72
[4]   Molecular basis of agonism and antagonism in the oestrogen receptor [J].
Brzozowski, AM ;
Pike, ACW ;
Dauter, Z ;
Hubbard, RE ;
Bonn, T ;
Engstrom, O ;
Ohman, L ;
Greene, GL ;
Gustafsson, JA ;
Carlquist, M .
NATURE, 1997, 389 (6652) :753-758
[5]   Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys [J].
Clarkson, TB ;
Anthony, MS ;
Jerome, CP .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (03) :721-726
[6]   Hormones and breast cancer: Evidence and implications for consideration of risks and benefits of hormone replacement therapy [J].
Colditz, GA .
JOURNAL OF WOMENS HEALTH, 1999, 8 (03) :347-357
[7]   The effect of raloxifene on risk of breast cancer in postmenopausal women - Results from the MORE randomized trial [J].
Cummings, SR ;
Eckert, S ;
Krueger, KA ;
Grady, D ;
Powles, TJ ;
Cauley, JA ;
Norton, L ;
Nickelsen, T ;
Bjarnason, NH ;
Morrow, M ;
Lippman, ME ;
Black, D ;
Glusman, JE ;
Costa, A ;
Jordan, VC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (23) :2189-2197
[8]   Structure and specificity of nuclear receptor-coactivator interactions [J].
Darimont, BD ;
Wagner, RL ;
Apriletti, JW ;
Stallcup, MR ;
Kushner, PJ ;
Baxter, JD ;
Fletterick, RJ ;
Yamamoto, KR .
GENES & DEVELOPMENT, 1998, 12 (21) :3343-3356
[9]   Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women [J].
Delmas, PD ;
Bjarnason, NH ;
Mitlak, BH ;
Ravoux, AC ;
Shah, AS ;
Huster, WJ ;
Draper, M ;
Christiansen, C .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (23) :1641-1647
[10]   Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): Multiple motifs with different binding specificities [J].
Ding, XF ;
Anderson, CM ;
Ma, H ;
Hong, H ;
Uht, RM ;
Kushner, PJ ;
Stallcup, MR .
MOLECULAR ENDOCRINOLOGY, 1998, 12 (02) :302-313